212 related articles for article (PubMed ID: 36813377)
1. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
2. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of factor XIa as a new approach to anticoagulation.
Schumacher WA; Luettgen JM; Quan ML; Seiffert DA
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):388-92. PubMed ID: 20139363
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
5. A review of emerging factor XI inhibitors.
Elsheikh S; Tidbury N; Lip GYH
Expert Opin Emerg Drugs; 2023 Mar; 28(1):43-53. PubMed ID: 36927160
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma.
Modrzycka S; Kołt S; Adams TE; Potoczek S; Huntington JA; Kasperkiewicz P; Drąg M
J Med Chem; 2023 Mar; 66(6):3785-3797. PubMed ID: 36898159
[TBL] [Abstract][Full Text] [Related]
7. A Review of FXIa Inhibition as a Novel Target for Anticoagulation.
Koulas I; Spyropoulos AC
Hamostaseologie; 2023 Feb; 43(1):28-36. PubMed ID: 36807817
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
9. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
[TBL] [Abstract][Full Text] [Related]
10. [New anticoagulants in 2024: Development of factor XI and XIa inhibitors].
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
Ann Biol Clin (Paris); 2024 Apr; 82(1):9-23. PubMed ID: 38638015
[TBL] [Abstract][Full Text] [Related]
11. Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis.
David T; Kim YC; Ely LK; Rondon I; Gao H; O'Brien P; Bolt MW; Coyle AJ; Garcia JL; Flounders EA; Mikita T; Coughlin SR
Sci Transl Med; 2016 Aug; 8(353):353ra112. PubMed ID: 27559095
[TBL] [Abstract][Full Text] [Related]
12. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
Salomon O; Gailani D
J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
[TBL] [Abstract][Full Text] [Related]
13. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
Prakash S; Mares AC; Porres-Aguilar M; Mukherjee D; Barnes GD
Vasc Med; 2024 Feb; 29(1):85-92. PubMed ID: 37947131
[TBL] [Abstract][Full Text] [Related]
14. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
15. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
16. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
D'Allesandro N; Cave B; Hough A
Future Cardiol; 2023 Aug; 19(10):477-486. PubMed ID: 37830334
[TBL] [Abstract][Full Text] [Related]
17. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
Vlădăreanu AM; Roşca A
Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.
Pireaux V; Tassignon J; Demoulin S; Derochette S; Borenstein N; Ente A; Fiette L; Douxfils J; Lancellotti P; Guyaux M; Godfroid E
J Am Coll Cardiol; 2019 Oct; 74(17):2178-2189. PubMed ID: 31648711
[TBL] [Abstract][Full Text] [Related]
20. Factor XIa inhibitors: A review of the patent literature.
Al-Horani RA; Desai UR
Expert Opin Ther Pat; 2016; 26(3):323-45. PubMed ID: 26881476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
